In brief: Select Vaccines, Psiron, Visiomed
Thursday, 21 April, 2005
Select Vaccines' (ASX:SLT) hepatitis E diagnostics kits have gained CE Mark approval for sale in the European Union. The company will sell the kits from June this year through its licencee, Genelabs
Psiron (ASX:PSX) has presented new data at a US medical conference confirming the anti-cancer effect in in vitro trials of its Coxsackievirus A21 virotherapy in cancer cell lines for breast, prostate and colon cancer and multiple myeloma.
Visiomed (ASX:VSG) subsidiary InfaMed has begun to sell its Funhaler children's asthma spacer device in Australian pharmacies.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
